Oct 8 (Reuters) – Merck & Co’s immunotherapy
Keytruda proved effective as an initial treatment for nearly a
quarter of patients with advanced bladder cancer too frail for
standard cisplatin…
The post Merck’s Keytruda achieves 24 pct response in bladder cancer study appeared first on NASDAQ.